| Date | Title | Description |
| 05.05.2018 | A life sciences firm run by a top VC and a cofounder of Alphabet’s life sciences arm, just raised its biggest fund yet | There’s no end to the number of fascinating devices and therapies being created right now in the fields of health and life sciences. The investors behind them are often pretty interesting, too, given the expertise needed to make informed be... |
| 16.11.2017 | Heartland startup funding in 2017 shows a North-South divide | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
While Silicon Valley is known as the heart of tec... |
| 16.11.2017 | Heartland startup funding in 2017 shows a North-South divide | While Silicon Valley is known as the heart of tech and home to the world’s top tier venture capital firms, other states and cities in the U.S. are beginning to show flourishing startup scenes — and VCs are noticing. Entrepreneurs in states ... |
| 15.09.2017 | Intarcia and Numab Reach Key Milestone | |
| 04.05.2017 | NEA’s Ed Mathers talks biopharma investment trends and why it’s worth sticking around | In a recent phone interview, Mathers discussed his investment principles ahead of a panel appearance at the upcoming MedCity INVEST conference, May 17-18 in Chicago.
By way of background, NEA is one of the largest tech and healthcare ventur... |
| 01.01.2017 | Intarcia Secures Second Close of the Series EE Equity Financing for an Additional $206M | Intarcia Therapeutics, Inc., today announced it has completed its second major close of the Series EE equity financing, and also entered into a relationship with the Bill & Melinda Gates Foundation to help prevent the spread of HIV in S... |
| 30.12.2016 | Intarcia Therapeutics Raises $206M in Second Close of Series EE Financing | Intarcia Therapeutics, Inc., a Boston, MA-based biopharmaceutical company, secured an additional $206M in the second close of the Series EE equity financing.
This financing followed the initial Series EE equity financing in September 2016 w... |
| 15.09.2016 | Intarcia Therapeutics Holds $215M First Close of Equity Financing | Intarcia Therapeutics, Inc., a Boston, MA-based biopharmaceutical company, held $215m first close of an equity financing.
Backers included institutional investors, family offices, Lucion Venture Capital Group (VC/PE fund located in China) a... |
| 17.06.2016 | Philanthropist Bill Gates talks public health, biotech, and the race for the White House | Bill Gates became one of the richest men in history after cofounding Microsoft. His impact on the world of personal computing cannot be overstated.
But for more than 15 years, he has devoted himself to philanthropic work through the Bill &a... |
| 18.08.2015 | Intarcia’s type 2 diabetes implant more effective than top-seller Januvia, could improve patient adherence | This is a big deal in terms of potential improvements to medication adherence: Patients can’t forget to take a medication if it’s implanted inside them. And it’s a bold move to go up against Januvia, given its broadscale brand recognition.
... |
| 01.05.2015 | Intarcia raises $225m to fund diabetes trial | Medtech funding for the week of April 27, 2015 | Intarcia adds $225m for Type II diabetes trial April 28, 2015 by Brad Perriello
Intarcia Therapeutics took its total raise to more than $1 billion with a $225 million funding round it plans to use to run clinical trials and commercialize it... |
| 28.04.2015 | Intarcia adds $225m for Type II diabetes trial | Intarcia Therapeutics yesterday took its total raise to more than $1 billion with a $225 million funding round it plans to use to run clinical trials and commercialize its the drug-device combination treatment it’s developing for Type II di... |
| 20.03.2015 | Intarcia and Numab to develop once-yearly therapies in diabetes, obesity and autoimmune indications | |
| 27.12.2014 | These 20 companies achieved $1B+ valuations in 2014 (updated) | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more.
Update 12/29: We’ve added AdYen.
Update 12/30: We’ve added IronSource.
Update 1/6/2015: We’ve added Credit Karma.
It is really, really ... |
| 27.12.2014 | These 20 companies achieved $1B+ valuations in 2014 (updated) | Update 12/29: We’ve added AdYen.
Update 12/30: We’ve added IronSource.
Update 1/6/2015: We’ve added Credit Karma.
It is really, really difficult to create a company and grow it to the point where investors believe it is worth $1 billion or ... |
| 12.11.2014 | Diabetes: Intarcia inks $1B development deal with Servier | Intarcia Therapeutics said today that French pharmaceutical independent Servier agreed to a deal to commercialize Intarcia’s implantable diabetes pump that could be worth some $1 billion.
Intarcia is developing ITCA 650, a matchstick-sized,... |
| 10.07.2014 | Venture-backed healthcare deals rise to $2.7B in Q2 | States accounting for the most deal activity Although Pennsylvania has a thriving biotechnology and healthcare community it doesn’t typically get as much recognition as California and Massachusetts. So it was interesting to see that Pennsyl... |
| 02.04.2014 | Intarcia Therapeutics Raises $200m Financing | Intarcia Therapeutics, a Boston, MA-based biotech company, raised $200m in financing.
The round was led by RA Capital with participation from Farallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf... |
| 01.04.2014 | Intarcia Secures $200M Financing |
BOSTON, MA, Intarcia Therapeutics, Inc. today announced the completion of another landmark private round of equity financing for $200 million.
>> Click here for more funding data on Intarcia Therapeutics
>> To export Intarci... |
| 16.11.2012 | Diabetes: Intarcia pulls down $210M for drug-device combo| Wall Street Beat | Intarcia Therapeutics said it’s reeled in financing worth a total of $210 million to further its drug-device combination treatment for Type II diabetes.
The Hayward, Calif.-based company, which is moving its headquarters to Boston, said the... |
| 15.11.2012 | Intarcia raises $210M for PhIII, once-yearly diabetes drug | Offering another example of just how expensive it is for a biotech company to develop a new diabetes therapy, Intarcia Therapeutics this morning unveiled a whopping $210 million in fresh financing to back its Phase III program for ITCA 650,... |
| 15.11.2012 | Intarcia Therapeutics Bags Mega $210M |
HAYWARD, CA, Financing consisted of $160 million in proceeds from a preferred stock private placement and $50 million in proceeds from a private debt placement.
>> Click here for more funding data on Intarcia Therapeutics
>>... |
| 04.10.2010 | Industry Ventures raising $300 million fund | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 08.09.2010 | What you need to know - Thursday 9/8/2010 | Kno raises $46 million, Amazon buys Amie Street, Aircell raises $176M, Google announcement coming?
It's a new day, and that means a new chance to begin your day well informed. Let's take a look at what's been going on in the last 24 hours.
... |
| 20.03.2007 | Intarcia restarts with $50M for hepatitis, diabetes treatments | Intarcia, an Emeryville biopharma company developing treatments for hepatitis C and type 2 diabetes, said it has raised $50 million in round of financing to restart the company.
New Leaf Venture Partners led the round, which included Quilve... |
| - | Venture-backed healthcare deals rise to $2.7B in Q2 | About $13.88 billion in venture capital backed 974 deals in the second quarter, the highest level since the first quarter of 2001, according to a new report by CB Insights. Healthcare accounted for a significant part of that. About $2.7 bil... |
| - | NEA’s Ed Mathers talks biopharma investment trends and why it’s worth sticking around | It’s safe to say Ed Mathers has accrued some industry know-how after 35 years in the biopharmaceutical industry — 15 of which have been spent on the investor side of the business.
Mathers is now in his ninth year as a partner at New Enterpr... |
| - | Intarcia’s type 2 diabetes implant more effective than top-seller Januvia, could improve patient adherence | In terms of controlling Type 2 diabetes and potentially obesity, Boston’s Intarcia Therapeutics just released some impressive Phase 3 findings: Its implantable device has been found to be more effective than Januvia, one of the top-selling ... |
| - | Industry Ventures raising $300 million fund | Industry Ventures, which invests in other venture and angel funds but has also made direct investments in healthcare, is raising a sixth fund after drawing down more than half of its 2-year-old, $265 million fund, according to VentureWire.
... |
